Emcure Pharmaceuticals (NSE:EMCURE) Loans Receivable: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
42 GF Score
Price ₹1,869.40
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Loans Receivable?

Emcure Pharmaceuticals NSE:EMCURE -0.48% 42 Loans Receivable is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 42/100. The stock has 5 warning signs investors should review.

Emcure Pharmaceuticals's Loans Receivable for the quarter that ended in Jun. 2026 was ₹0 Mil.

Emcure Pharmaceuticals Loans Receivable Related Terms

Emcure Pharmaceuticals Loans Receivable Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Loans Receivable Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:EMCURE
42GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of ₹0 Mil mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Loans Receivable of ₹0 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Emcure Pharmaceuticals and its competitors.
Is Emcure Pharmaceuticals' Loans Receivable too high?
Emcure Pharmaceuticals' current Loans Receivable is ₹0 Mil. Overall, Emcure Pharmaceuticals has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Loans Receivable compare to ZTS?
Emcure Pharmaceuticals' Loans Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Loans Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Loans Receivable of ₹0 Mil. The current Loans Receivable is ₹0 Mil. Emcure Pharmaceuticals' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Loans Receivable is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
42GF Score

Get the complete analysis for NSE:EMCURE

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,869.40
Price